Kymera Therapeutics Inc KT-474 Phase 1 Update Corporate Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Great. And just in terms of the FDA discussions, if there's any more color that you can give, I guess, kind of around how those went any feedback or commentary on the safety of header functional degrader, is any residual concerns or just any what the key topics of discussion were in those conversations? Just any color you could provide on sort of the regulatory feedback around the lifting of the partial hold.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : My first one is on the -- your continuing dose escalation in your SAD. Just wondering since you have seen pretty positive signal already, why do you plan to still continue to dose escalation this portion?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Got it. And the second question, I wanted to follow up on the PBMC versus skin and spin tissue distribution, I guess, any color you can provide around whether there is a differential between the PBMC and split and the potential biological significance of that. I see on your slide in dogs, you see the drug seems to have more distribution or the knockdown is more significant in the skin. Broadly, I think also in your toolbox, you have tissue-specific degraders in development, I guess, are you thinking potentially use some more tissue-specific degraders or not?